Paper
0
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Authors
Paul Richardson,David Siegel
Ravi Vij,Craig Hofmeister,Rachid Baz,Sundar Jagannath,Christine Chen,Sagar Lonial,Andrzej Jakubowiak,Nizar Bahlis,Kevin Song,Andrew Belch,Noopur Raje,Chaim Shustik,Suzanne Lentzsch,Martha Lacy,Joseph Mıkhael,Jeffrey Matous,David Vesole,Min Chen,Mohamed Zaki,Christian Jacques,Zhinuan Yu
+21 authors
,Kenneth AndersonJournal
Published
Jan 14, 2014
Show more
Save
Tip0
TipSave
Abstract
Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.